WO2005080976A1 - 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法 - Google Patents
統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法 Download PDFInfo
- Publication number
- WO2005080976A1 WO2005080976A1 PCT/JP2005/002838 JP2005002838W WO2005080976A1 WO 2005080976 A1 WO2005080976 A1 WO 2005080976A1 JP 2005002838 W JP2005002838 W JP 2005002838W WO 2005080976 A1 WO2005080976 A1 WO 2005080976A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- memory
- schizophrenia
- task
- learning
- dysfunction
- Prior art date
Links
- 230000015654 memory Effects 0.000 title claims abstract description 105
- 201000000980 schizophrenia Diseases 0.000 title claims abstract description 69
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 230000004064 dysfunction Effects 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 38
- 229940124597 therapeutic agent Drugs 0.000 title claims description 35
- 238000012750 in vivo screening Methods 0.000 title claims description 7
- 230000006870 function Effects 0.000 claims abstract description 16
- 238000010171 animal model Methods 0.000 claims abstract description 14
- 238000012216 screening Methods 0.000 claims abstract description 11
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 238000012360 testing method Methods 0.000 claims description 58
- 238000012549 training Methods 0.000 claims description 44
- 241001465754 Metazoa Species 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 102000005962 receptors Human genes 0.000 claims description 29
- 108020003175 receptors Proteins 0.000 claims description 29
- 239000004480 active ingredient Substances 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 14
- 229960004170 clozapine Drugs 0.000 claims description 14
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- -1 phenoxy, phenylthio Chemical group 0.000 claims description 14
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 11
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 10
- 229960001432 lurasidone Drugs 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 229960004431 quetiapine Drugs 0.000 claims description 10
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 150000003949 imides Chemical class 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 6
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229960003299 ketamine Drugs 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 5
- 150000001721 carbon Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 230000008485 antagonism Effects 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 229940076279 serotonin Drugs 0.000 claims description 4
- 239000003727 serotonin 1A antagonist Substances 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- XLBVNMSMFQMKEY-SCSAIBSYSA-N (2r)-2-(methylamino)pentanedioic acid Chemical compound CN[C@@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-SCSAIBSYSA-N 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004373 acetylcholine Drugs 0.000 claims description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000005277 alkyl imino group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 229950010883 phencyclidine Drugs 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 17
- 208000010877 cognitive disease Diseases 0.000 abstract description 15
- 208000028017 Psychotic disease Diseases 0.000 abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 25
- 230000004044 response Effects 0.000 description 11
- 208000028698 Cognitive impairment Diseases 0.000 description 10
- 229940044551 receptor antagonist Drugs 0.000 description 9
- 239000002464 receptor antagonist Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
- 206010027175 memory impairment Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000000561 anti-psychotic effect Effects 0.000 description 7
- 239000003693 atypical antipsychotic agent Substances 0.000 description 7
- 229940127236 atypical antipsychotics Drugs 0.000 description 7
- 239000000164 antipsychotic agent Substances 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940005529 antipsychotics Drugs 0.000 description 4
- 229960003878 haloperidol Drugs 0.000 description 4
- 201000003723 learning disability Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 3
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008717 functional decline Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000006386 memory function Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229960004372 aripiprazole Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000027928 long-term synaptic potentiation Effects 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 102100039693 D-amino acid oxidase activator Human genes 0.000 description 1
- 102000005611 Dysbindin Human genes 0.000 description 1
- 108010045061 Dysbindin Proteins 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000886242 Homo sapiens D-amino acid oxidase activator Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 102000048238 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007595 memory recall Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000006977 prepulse inhibition Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000000371 schizophrenia 5 Diseases 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
Definitions
- the present invention relates to a method for in vivo screening of a therapeutic agent for improving memory and learning dysfunction in schizophrenia.
- Dalmic acid is the most common excitatory neurotransmitter in the central nervous system, and its receptors are NMDA type, a-amino-3_hydroxy-5-metliy 4- 4-isoxazolepropionic (AMPA) type, kainate Type and metabolic regulation type (metabo tropic type).
- NMDA receptors have been shown to play an important role in the establishment of long-term potentiation (LTP), which is a basic electrophysiological process of memory and learning functions (Sc ience 285: 1870-1874 (1999)).
- NMDA receptor antagonists are used in a variety of memory learning tasks such as passive avoidance responses, radial mazes, T or Y-mazes, water mazes, place or object recognition, autoshaping learning tasks, and lever pushing tasks ⁇ It is known to cause learning disabilities (Brain Res Rev 41: 268-287 (2003)). In humans, it has been reported that NMDA receptor antagonists such as PCP and ketamine cause cognitive impairment (Psychopharmacology 169: 215-233 (2003)). In other words, it is a consistent finding at the electrophysiological, animal, and human levels that DA-type receptors play an important role in memory and learning processes.
- NMDA receptor function is the most promising hypothesis as a mechanism of schizophrenia. This hypothesis is formed from the following four points.
- the NMDA receptor antagonists PCP and ketamine cause major symptoms of schizophrenia, including cognitive impairment and positive / negative symptoms in healthy subjects, and exacerbation of symptoms in schizophrenia patients (Am J Psychiatry 158: 1367-1377 (2001), Psychopharmacology 169: 215-233 (2003)),
- (ii) glycine, D-known to enhance NMM receptor function serine and])-Cycloserine has been reported to enhance the efficacy of antipsychotics in schizophrenic patients and improve negative symptoms and cognitive dysfunction (Am J Psychiatry 158: 1367-1377 (2001), Psychopharmacology 169: 215-233 (2003)) 0
- Variation in the amount of daltamic acid itself or the amount of the endogenous substance N-acetyl-aspartyl glutamate (NAAG) with NMDA antagonism is seen in schi
- Schizophrenia is associated with a variety of cognitive dysfunctions such as attention, memory, learning, and executive functions, and among them, there are reports that certain memory functions are selectively and seriously affected. Can be seen.
- memories can be broadly divided into procedural memory and declarative memory. Declarative memory is more short-term, short-term memory / working memory, and long-term reference. It can be classified as long-term memory / reference memory, but in schizophrenia, declarative memory including both working memory and reference memory is selectively affected, and Reference memory impairments have been reported to be most severe. Recently, it has been reported that such cognitive impairment, including reference memory impairment, is the most important predictor of the social daily and occupational abilities and duality of life of schizophrenic patients.
- animals can perform avoidance reactions such as shock shock (passive and active avoidance reactions), the behavioral ice maze task of swimming to reach an invisible platform below the water, and maze tasks. Behaviors such as baiting and avoiding electric shock (radial maze task, Y or ⁇ -shaped maze task), recognizing and exploring new places or objects, pushing levers to bait, etc. Learning and acquiring its memory. After a period of time, the animals are returned to the exact same experimental environment and tested to recall the acquired memory.
- avoidance reactions such as shock shock (passive and active avoidance reactions)
- the behavioral ice maze task of swimming to reach an invisible platform below the water and maze tasks. Behaviors such as baiting and avoiding electric shock (radial maze task, Y or ⁇ -shaped maze task), recognizing and exploring new places or objects, pushing levers to bait, etc. Learning and acquiring its memory. After a period of time, the animals are returned to the exact same experimental environment and tested to recall the acquired memory.
- animals memorize all the specific environments and stimuli that are presented in a specific order during training.Training and testing are necessary to correctly determine the success or failure of memory acquisition during training. Need to be implemented in a completely similar environment.
- ethanol and marauding DA receptor antagonists may cause memory recall abnormalities when administered only during training in the reference memory task and not during testing (Brain Res. 706: 227-232 (1996), Pharmcol Biochem Behav 69: 585-593 (2001)).
- the animal has acquired a reference memory that depends on the brain environment caused by the administration of these drugs, and in fact, the administration of these drugs both during training and testing can correct the acquired memories. I know it will be recalled.
- An in vivo screening method for predicting whether a test compound has the potential to improve memory and learning dysfunction in schizophrenia comprising an N-methyl-D-glutamate as an animal model for schizophrenia. -Using a model with aspartate (NMDA) type receptor dysfunction, using a reference memory task, and evaluating the memory and learning functions
- the reference memory task is a passive avo idance task, an active avoi dance task, a water maze task, a radial maze task. task), T or Y maze task, place recognition task (pace recognit ion task), obj ect recognit ion task, autosha ping learning task ;, Reno ⁇ , the method according to 1 above, which is a lever-pressing task.
- the reference memory task consists of two sessions, training and testing. During training, one of the tasks described in 2 above is learned, and the memory is acquired (acduis initiation). The method according to the above item 1, wherein the test is performed after a certain period of time, and the task is to quantify the memory retention (retention) and retrieval (retrieval) ability during the test.
- the DA-type receptor dysfunction model uses a compound with NMDA-type receptor antagonism, such as HK_801, phencyclidine (PCP), ketamine, or a derivative thereof, and uses these as a reference for training in memory tasks. 2.
- NMDA-type receptor antagonism such as HK_801, phencyclidine (PCP), ketamine, or a derivative thereof.
- the NMDA-type receptor dysfunction model has ⁇ the mutation, overexpression, or deletion of the gene of the DA-receptor constituent protein or related protein. 2.
- a therapeutic agent for memory and learning dysfunction in schizophrenia which comprises, as an active ingredient, a substance selected using the screening method according to any one of the above 1 to 5.
- a therapeutic agent for memory and learning dysfunction in schizophrenia comprising a serotonin 5-HT 1A antagonist selected as an active ingredient using the screening method according to any one of 1 to 5 above.
- a therapeutic agent for memory / learning dysfunction in schizophrenia which comprises, as an active ingredient, an acetylcholine synthase inhibitor selected using the screening method according to any one of the above 1 to 5.
- a therapeutic agent for memory and learning dysfunction in schizophrenia which contains aricept as an active ingredient.
- a therapeutic agent for memory and learning dysfunction in schizophrenia containing quetiapine as an active ingredient containing quetiapine as an active ingredient.
- a therapeutic agent for memory and learning dysfunction in schizophrenia containing clozapine as an active ingredient containing clozapine as an active ingredient.
- R 1 , R 2 , R 3 , and R 4 each independently represent a hydrogen atom or lower alkyl. However, when R 1 and R 2 or R 1 together Or a hydrocarbon ring or R 1 may be taken together to form an aromatic hydrocarbon ring, wherein the hydrocarbon ring may be bridged with a lower alkylene or an oxygen atom. And the hydrocarbon ring may be substituted with at least one alkyl, and n represents 0 or 1.).
- D is the formula
- A represents a lower alkylene or a hydrocarbon ring which may be bridged with an oxygen atom.
- the lower alkylene and the hydrocarbon ring may be substituted with at least one alkyl.
- P and Q are each 0, 1 Or represents 2.
- G is N, CH or C ⁇ ⁇
- Ar is an aromatic heterocyclic group, aromatic hydrocarbon group, benzoyl, phenoxy group Or G represents phenylthio, or G represents a carbon atom, and Ar represents biphenylmethylidene.
- aromatic heterocyclic group aromatic hydrocarbon group, benzoyl, phenoxy, phenylthio and biphenylmethylidene may be substituted with at least one lower alkyl, lower alkoxy or halogen atom.
- a therapeutic agent for memory and learning dysfunction in schizophrenia which contains an imide derivative represented by the formula or an acid addition salt thereof as an active ingredient.
- Ar is an aromatic heterocyclic group condensed with a benzene ring, naphthyl, benzoyl, phenoxy or phenylthio (the aromatic heterocyclic group condensed with the benzene ring, naphthyl, benzoisle, phenoxy and Phenylthio may be substituted by at least one lower alkyl, lower alkoxy or halogen atom.
- a therapeutic agent for memory and learning dysfunction in schizophrenia comprising as an active ingredient the imide derivative or the acid addition salt thereof according to the above item 16, which is N, CH or COH.
- L represents a single bond or a double bond.
- E represents a lower alkylene or an oxygen atom which may be substituted with a lower alkyl.
- R 5 represents a hydrogen atom or a lower alkyl.
- B represents the meaning described in the above 14.
- R 6 , R 7 , R 8 , R 9 , R ′ °, R, R 12 , R 13 , R 14 , and R 15 are each a hydrogen atom or lower alkyl, or R 6 , R 7 , R 8, R 9, R 10 , R n, represents an R 1 2, R 13, R 14, R 15 two are bonded double bonds ⁇ in.
- B represents the meaning of the.
- R 16 and R 17 each independently represent a hydrogen atom or lower alkyl, or R 6 , R 17 together form a saturated hydrocarbon ring.
- R 5 and B have the same meanings as defined above.
- a therapeutic agent for memory and learning dysfunction in schizophrenia comprising the imide derivative or an acid addition salt thereof according to the above item 16, as an active ingredient.
- the compound represented by the general formula [1] is luras idone
- [Z represents divalent sulfur, imiso, lower alkyl imino,
- Ri represents hydrogen, alkyl having 1 to 5 carbon atoms
- Ri 2 represents hydrogen, alkyl having 1 to 5 carbons, phenyl, 5- substituted phenyl, aminoamino having 1 to 5 carbons, lower alkylaminoalkyl having 2 to 8 carbons, lower alkylamizo, amino, lower alkylamino Represents, or
- R xx and Ri 2 are joined together with N to form 1-pyrrolidinyl, piperidino, morpholino, thiomorpholino, 1-piperazinyl, 4-lower alkyl-1-piperazinyl, 4- (hydroxy lower alkyl) —1-piperazinyl or 4- ( Lower alkoxy lower alkyl) may represent 1-piperazinyl.
- R x 3> Rl 4 and 5 represent hydrogen, halogen, hydroxyl, trifluoromethyl, lower alkyl, lower alkoxy, lower alkylthio]
- a schizophrenia containing a compound represented by the formula or an acid addition salt thereof as an active ingredient a part of atypical antipsychotics, not haloperidol Specific methods for finding memory-specific learning effects were shown. This result is consistent with the fact that haloperidol has no clinical effect on improving cognitive impairment and that atypical antipsychotics have an effect on improving cognitive impairment. As a result, it has become possible to provide a method of screening for a therapeutic agent for cognitive dysfunction of schizophrenia and a specific therapeutic agent.
- the present invention relates to an in vivo screening method for predicting whether or not a test compound has the potential to improve memory and learning dysfunction in schizophrenia, and comprising an NMDA-type receptor as an animal model for schizophrenia. Using a model with functional decline, using a reference memory task, and evaluating a memory and learning function.
- the reference memory task includes a passive avoidance response task, an active avoidance response task, a water maze task, a radial maze task, a T or Y-shaped maze task, a location recognition task, an object recognition task, and an autoshaping learning tasL lever push task. Can be used.
- the reference memory task consists of two sessions, training and testing, in which a task in training is learned, the memory is acquired, a test is performed after a certain period of training, and the memory of the test is tested.
- Maintenance ⁇ This is an issue to quantify recall ability.
- Marauder DA-type receptor function decline models include: ⁇ Use compounds with DA-type receptor antagonism, for example, MK-801, PCP, keto amine, or their derivatives, and refer to these at the time of training in memory tasks.
- a model can be used that is created by administering to animals at both times during the test, or chronically administering to animals during a period that includes training and testing.
- a mutation or overexpression or deletion of a gene of a constituent protein of the NMDA-type receptor or a related protein can be used for reference memory training and testing.
- animal models with NMDA-type receptor dysfunction can also be used.
- Test compounds include haloper idol, a typical antipsychotic, clozapine Quetiapine, ri sper idone, ol anzapine, aripiprazo le, a non-breast type scleroderma, and new antipsychotics under development.
- luras idone was used by suspending in 0.5% Methyl Cellulose (MC).
- MC Methyl Cellulose
- serotonin 5-HT1A receptor antagonist WAY-100635 and noradrenaline ⁇ 2 receptor antagonist 1-PP were dissolved in physiological saline (Otsuka Pharmaceutical).
- MK-801 hydrogen maleate (SIGMA-ALDRICH M-107) was dissolved in physiological saline (Otsuka Pharmaceutical) as an NMDA receptor antagonist.
- the test compound was administered orally or intraperitoneally 1 hour before training in a passive avoidance response task with 0.3 to 10 mg / kg of a test compound and 0.5% MC or saline as a control, and MK-801 was administered.
- Saline was trained and administered subcutaneously 30 minutes before the test at 0.05 mg / kg or its control.
- MK-801 was administered during training, and physiological saline was administered during testing. In each case, the dose was 5 inL / kg.
- an experimental device consisting of a light / dark experimental box, a slide door separating the light / dark box, and a shock generator Using Hara Medical Industry Co., Ltd., PA-2030A, PA-3001A), it was carried out as follows. That is, on the first day of the experiment, after administration of the test compound and MK-801, rats were placed in the light box of the experimental apparatus with their backs facing the dark box side, and 10 seconds later, the slide door provided at the boundary of the light / dark box was opened. When the rats entered the dark box according to their habits, the sliding door was quickly closed, and 3 seconds after entering the dark box, a 0.5 mA, 3 second electric shock was applied.
- the time from when the rat entered the box was measured as the step-through latency.
- training was terminated and training was not completed and was excluded from the following tests.
- the test was performed approximately 24 hours after training. Thirty minutes before the test, subcutaneous administration of MK-801 or a saline solution thereof was performed. The operation during the test was the same as during the training except that no electric shock was given. The travel latency during the test was measured up to a maximum of 300 seconds, and those exceeding 300 seconds were set to 300 seconds.
- the number of animals that showed 300 seconds during the test was counted, and the incidence was calculated as a percentage (defined as% of animal s avoiding) for each group. In% of animal s avo id ing of statistical analysis, using the correction with ⁇ 2 test of Bonferroni. The animals used were 10-25 animals per group, and the data show percentages.
- the drug is administered alone without using MK-801, and the dose of the drug that induces learning disability in the passive avoidance response is determined.
- the dose that did not cause harm was taken as the dose in the MK-801 model (Table 1).
- the dose (ED50, mg / kg p. 0.) that inhibits rat amphetamine-induced hyperactivity, which reflects antipsychotic effects, by 50% is 65 in clozapine and about 100 in auet iapine I know.
- clozapine potion (1116 3 11 ⁇ ) exerts a memory-learning disorder ameliorating effect at doses 65-217 times and -10 times lower than the ED50 of antipsychotic effect, respectively.
- the daily clinical dose of clozapine as an antipsychotic is 150-750 mg, memory in schizophrenia To improve learning dysfunction, the dose is 150 / 217-750 / 65 (i.e., 0.7-11.5 mg), which is about 3 times wider than before and after 0.3-4.5.5 mg, preferably 0. 7-11. 5 mg dose
- the daily clinical dose of Quet iapine is 150_900 mg as an antipsychotic, to improve memory and learning dysfunction in schizophrenia 5-270 mg, preferably 15-9 (kg dose), which is 150 / 10-900 / 100 (i.e., 15-90 mg) expanded about three times before and after. .
- Example 1 0.75 mg / kg of PCP HC1 was used instead of 0.05 mg / kg of MK-801, and this was used as a memory. It can be used to evaluate the effects of test compounds on improving memory and learning disabilities.
- Example 3 0.75 mg / kg of PCP HC1 was used instead of 0.05 mg / kg of MK-801, and this was used as a memory. It can be used to evaluate the effects of test compounds on improving memory and learning disabilities.
- Example 3
- Example 1 ketamine was used in place of MK-801 and PCP HC1, and the other experimental conditions were exactly the same as in Example 1 to evaluate the memory compound learning ameliorating effect of the test compound.
- Examples 13 to 13 instead of subcutaneous administration of marauder DA type receptor antagonists such as MK-801, PCP HC1 and ketamine before training and testing, these drugs were immediately injected into ALZET os motic pu. By implanting it subcutaneously on the dorsal side of an animal, chronic subcutaneous administration can be performed for a period including both training and testing, and memory and learning dysfunction can be caused. The ability to improve memory and learning dysfunction can be evaluated.
- an animal having a mutation, overexpression or deletion of a gene of a constituent protein of an NMDA-type receptor or a related protein can be used.
- Example 1-5 instead of the passive avoidance reaction task, an active avoidance reaction task, a water maze task, a radial maze task, a T or Y-shaped maze task, a place recognition task, an object recognition task, an autoshaping learning task,
- an active avoidance reaction task instead of the passive avoidance reaction task, an active avoidance reaction task, a water maze task, a radial maze task, a T or Y-shaped maze task, a place recognition task, an object recognition task, an autoshaping learning task.
- Table 1 shows the effects of drugs on MK-801-induced memory learning impairment in the passive avoidance response in rats.
- test shows the effect of the drug on animals that showed a step-through latency of at least 300 seconds, ie, the percentage of animals that showed significant memory retention,% of animal savoiding).
- the lowest dose at which memory / learning impairment was caused by the use of the drug alone was given at the right end of the table.
- the numerical values in the table indicate% of animals avoiding. In the same passive avoidance response test, the lowest dose that causes memory and learning impairment by using the drug alone was given to the right end of the table.
- n 10-25.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/589,804 US20070160537A1 (en) | 2004-02-20 | 2005-02-16 | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
EP05710541A EP1726952A4 (en) | 2004-02-20 | 2005-02-16 | METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA |
JP2006510283A JP4847320B2 (ja) | 2004-02-20 | 2005-02-16 | 統合失調症の記憶・学習機能障害治療薬のinvivoスクリーニング方法 |
US12/401,958 US8835438B2 (en) | 2004-02-20 | 2009-03-11 | Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone |
US14/460,316 US20140356292A1 (en) | 2004-02-20 | 2014-08-14 | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-044986 | 2004-02-20 | ||
JP2004044986 | 2004-02-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/589,804 A-371-Of-International US20070160537A1 (en) | 2004-02-20 | 2005-02-16 | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
US12/401,958 Division US8835438B2 (en) | 2004-02-20 | 2009-03-11 | Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005080976A1 true WO2005080976A1 (ja) | 2005-09-01 |
Family
ID=34879367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/002838 WO2005080976A1 (ja) | 2004-02-20 | 2005-02-16 | 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法 |
Country Status (4)
Country | Link |
---|---|
US (3) | US20070160537A1 (ja) |
EP (2) | EP2357474A1 (ja) |
JP (1) | JP4847320B2 (ja) |
WO (1) | WO2005080976A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018506569A (ja) * | 2015-02-25 | 2018-03-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
WO2020184676A1 (ja) * | 2019-03-13 | 2020-09-17 | 国立大学法人群馬大学 | Nmda受容体阻害活性のハイスループット評価方法 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9174975B2 (en) | 2002-08-22 | 2015-11-03 | Sumitomo Dainippon Pharma Co., Ltd | Remedy for integration dysfunction syndrome |
CA2531980C (en) | 2003-06-23 | 2013-09-17 | Dainippon Sumitomo Pharma Co., Ltd. | Imide derivatives as therapeutic agents for senile dementia |
DE602004020263D1 (de) | 2003-12-22 | 2009-05-07 | Acadia Pharm Inc | Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen |
WO2005080976A1 (ja) | 2004-02-20 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法 |
EP1891956B1 (en) * | 2005-06-13 | 2012-08-29 | Dainippon Sumitomo Pharma Co., Ltd. | Solubilization preparation |
MY153868A (en) | 2007-04-04 | 2015-03-30 | Merck Sharp & Dohme | Therapeutic agents |
US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
CA2836066A1 (en) * | 2011-05-13 | 2012-11-22 | Dainippon Sumitomo Pharma Co., Ltd. | Treatment and management of cns disorders |
US20140350029A1 (en) * | 2011-12-02 | 2014-11-27 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
WO2015195478A1 (en) | 2014-06-16 | 2015-12-23 | Johnson Matthey Public Limited Company | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
WO2016149248A1 (en) * | 2015-03-15 | 2016-09-22 | Emory University | N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003135074A (ja) * | 2001-11-05 | 2003-05-13 | Japan Science & Technology Corp | ドレブリンa発現抑制動物神経細胞及び非ヒトモデル動物 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
DK36291D0 (da) | 1991-03-01 | 1991-03-01 | Lundbeck & Co As H | Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser |
GB9202915D0 (en) | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
IL110011A (en) | 1994-06-13 | 2004-09-27 | Yeda Res & Dev | Pharmacological preparations for the treatment of schizophrenia |
JP3948744B2 (ja) * | 1994-11-04 | 2007-07-25 | 大日本住友製薬株式会社 | 新規なラクタム誘導体 |
JP3775823B2 (ja) | 1995-06-09 | 2006-05-17 | 大日本住友製薬株式会社 | 新規なイミド誘導体 |
PT1073432E (pt) | 1998-04-14 | 2007-10-22 | Gen Hospital Corp | Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia |
JP2000281576A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | イミド誘導体を含有するプロテオグリカン生成促進剤 |
AR027134A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de indol. |
US6946474B2 (en) | 2000-09-14 | 2005-09-20 | Merck & Co., Inc. | Nitrogen-containing compounds and their use as glycine transport inhibitors |
EP1974724A3 (en) | 2000-09-22 | 2008-11-12 | Dainippon Sumitomo Pharma Co., Ltd. | Oral preparations with good disintegration |
CA2431041A1 (en) | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
BR0210391A (pt) | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
JP4175800B2 (ja) | 2001-11-27 | 2008-11-05 | 住友化学株式会社 | イミド誘導体の製造方法 |
EP1480629A1 (en) | 2002-02-08 | 2004-12-01 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
US9174975B2 (en) | 2002-08-22 | 2015-11-03 | Sumitomo Dainippon Pharma Co., Ltd | Remedy for integration dysfunction syndrome |
CA2531980C (en) | 2003-06-23 | 2013-09-17 | Dainippon Sumitomo Pharma Co., Ltd. | Imide derivatives as therapeutic agents for senile dementia |
WO2005080976A1 (ja) | 2004-02-20 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法 |
US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
TW200812993A (en) | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
WO2008054793A2 (en) | 2006-10-30 | 2008-05-08 | Sanrx Pharmaceuticals, Inc. | Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon |
MY153868A (en) | 2007-04-04 | 2015-03-30 | Merck Sharp & Dohme | Therapeutic agents |
-
2005
- 2005-02-16 WO PCT/JP2005/002838 patent/WO2005080976A1/ja active Application Filing
- 2005-02-16 US US10/589,804 patent/US20070160537A1/en not_active Abandoned
- 2005-02-16 EP EP11160001A patent/EP2357474A1/en not_active Ceased
- 2005-02-16 JP JP2006510283A patent/JP4847320B2/ja active Active
- 2005-02-16 EP EP05710541A patent/EP1726952A4/en not_active Withdrawn
-
2009
- 2009-03-11 US US12/401,958 patent/US8835438B2/en active Active
-
2014
- 2014-08-14 US US14/460,316 patent/US20140356292A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003135074A (ja) * | 2001-11-05 | 2003-05-13 | Japan Science & Technology Corp | ドレブリンa発現抑制動物神経細胞及び非ヒトモデル動物 |
Non-Patent Citations (4)
Title |
---|
EBIHARA ET AL: "Togo Shicchosho no Dobutsu Model.", IGAKU NO AYUMI., vol. 208, no. 3, 2004, pages 138 - 142, XP002991290 * |
ENOMOTO ET AL: "Dobutsu Model o Mochiita Ko Seishin'byoyaku no Kaihatsu.", BRAIN SCIENCE., vol. 25, no. 5, 2003, pages 437 - 444, XP002991289 * |
SAJI ET AL: "Shinkei Kairomo Keisei to Kofunsei Synapse Kasosei ni Kansuru Kodogakuteki Kenkyu NMDA Juyotai Kaiba Knockdown Dobutsu no Togo Shicchoshoyo no Ninchi Shogai.", SHINKEI KAIROMO KEISEI SHOGAI NO BUNSHI KIKO NI KANSURU KENKYU., 2003, pages 13 - 20, XP002991291 * |
See also references of EP1726952A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018506569A (ja) * | 2015-02-25 | 2018-03-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
WO2020184676A1 (ja) * | 2019-03-13 | 2020-09-17 | 国立大学法人群馬大学 | Nmda受容体阻害活性のハイスループット評価方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4847320B2 (ja) | 2011-12-28 |
US8835438B2 (en) | 2014-09-16 |
EP1726952A1 (en) | 2006-11-29 |
EP1726952A4 (en) | 2008-06-18 |
JPWO2005080976A1 (ja) | 2007-10-25 |
US20140356292A1 (en) | 2014-12-04 |
US20090176800A1 (en) | 2009-07-09 |
US20070160537A1 (en) | 2007-07-12 |
EP2357474A1 (en) | 2011-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005080976A1 (ja) | 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法 | |
JP6542847B2 (ja) | パーキンソン病におけるジスキネジアを治療するための新規d3ドーパミン受容体アゴニスト | |
Howell et al. | Monoamine transporters and psychostimulant addiction | |
US6166008A (en) | Treatment of schizophrenia with ampakines and neuroleptics | |
DK2282778T3 (en) | NEW THERAPEUTIC APPROACHES TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES THROUGH A MODULATION OF ANGIOGENIC | |
PT2083811T (pt) | Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo | |
JP7377548B2 (ja) | 抗精神病薬及びその用途 | |
US20060035889A1 (en) | Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists | |
JP2019509278A (ja) | Fxrアゴニストを使用するための方法 | |
CN1427720A (zh) | 用于治疗耐受性和依赖性的促代谢谷氨酸受体拮抗剂 | |
JP6002778B2 (ja) | アルコール依存症および乱用の治療において使用するためのorl−1受容体アンタゴニストとしてのスピロチエノピラン−ピペリジン誘導体 | |
CA2814828C (en) | Method of treatment for mental disorders | |
Jain et al. | The role of NMDA receptor antagonists in nicotine tolerance, sensitization, and physical dependence: a preclinical review | |
Nakashima et al. | TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models | |
WO2009036340A2 (en) | Mpzp: a small molecule corticotropin-releasing factor type 1 receptor (crf1) antagonist | |
PT1830833E (pt) | Combinação de um inibidor do transportador da glicina (glyt1) e um antipsicótico para o tratamento de sintomas de esquizofrenia, bem como a sua preparação e sua utilização | |
Hashimoto | Glycine transporter-1 inhibitors as novel therapeutic drugs for schizophrenia | |
MX2011013860A (es) | Inversion de la discinesia inducida por levopoda mediante los ligandos del receptor nicotinico neural. | |
WO2012040444A2 (en) | Treatment of patients with incipient alzheimer's disease | |
Albert et al. | Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia | |
JP2012102069A (ja) | 早漏治療剤 | |
JP2020510001A (ja) | 非アルコール性脂肪性肝疾患と非アルコール性脂肪性肝炎の予防および/または処置に使用するための化合物 | |
NZ624201B2 (en) | Spirothienopyran- piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510283 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007160537 Country of ref document: US Ref document number: 10589804 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005710541 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005710541 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10589804 Country of ref document: US |